AstraZeneca (AZ) has shrugged off a “significant... revolt”, says Ian Johnston in the Financial Times. Shareholders approved a potential £1.8m pay rise for CEO Pascal Soriot, but more than a third of them voted against a package advisers had called “excessive”. Critics had argued that Soriot was
Astra’s spoonful of sugar
Apr 19, 2024
2 minutes
You’re reading a preview, subscribe to read more.
Start your free 30 days